These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 18948375

  • 1. Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.
    Singer CF, Hudelist G, Fuchs EM, Köstler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Lamm W, Rudas M, Czerwenka K, Kubista E.
    Endocr Relat Cancer; 2009 Mar; 16(1):73-83. PubMed ID: 18948375
    [Abstract] [Full Text] [Related]

  • 2. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D.
    Cancer; 2003 Sep 15; 98(6):1123-30. PubMed ID: 12973835
    [Abstract] [Full Text] [Related]

  • 3. EGFR activity in HER-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of Her-2/neu and EGFR.
    Gschwantler-Kaulich D, Hudelist G, Koestler WJ, Czerwenka K, Mueller R, Helmy S, Ruecklinger E, Kubista E, Singer CF.
    Oncol Rep; 2005 Aug 15; 14(2):305-11. PubMed ID: 16012707
    [Abstract] [Full Text] [Related]

  • 4. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.
    Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K, Singer CF.
    Oncol Rep; 2007 Aug 15; 18(2):299-304. PubMed ID: 17611648
    [Abstract] [Full Text] [Related]

  • 5. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
    Pagano E, Calvo JC.
    J Cell Biochem; 2003 Oct 15; 90(3):561-72. PubMed ID: 14523990
    [Abstract] [Full Text] [Related]

  • 6. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Yoon SO, Shin S, Lipscomb EA.
    Cancer Res; 2006 Mar 01; 66(5):2732-9. PubMed ID: 16510594
    [Abstract] [Full Text] [Related]

  • 7. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG, Uner A, Yildiz I, Guler G, Takahashi M.
    Pathol Res Pract; 2009 Mar 01; 205(6):403-8. PubMed ID: 19232840
    [Abstract] [Full Text] [Related]

  • 8. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.
    Cicenas J, Urban P, Küng W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenberger-Castori S.
    Eur J Cancer; 2006 Mar 01; 42(5):636-45. PubMed ID: 16414259
    [Abstract] [Full Text] [Related]

  • 9. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 01; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 10. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
    Cuny M, Simony-Lafontaine J, Rouanet P, Grenier J, Valles H, Lavaill R, Louason G, Causse A, Lequeux N, Thierry C.
    Oncol Res; 1994 Feb 01; 6(4-5):169-76. PubMed ID: 7841539
    [Abstract] [Full Text] [Related]

  • 11. Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
    Ooi A, Zen Y, Ninomiya I, Tajiri R, Suzuki S, Kobayashi H, Imoto I, Dobashi Y.
    Pathol Int; 2010 Jun 01; 60(6):466-71. PubMed ID: 20518902
    [Abstract] [Full Text] [Related]

  • 12. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 01; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 13. Residual disease after re-excision for tumour-positive surgical margins in both ductal carcinoma in situ and invasive carcinoma of the breast: The effect of time.
    Schouten van der Velden AP, Van de Vrande SL, Boetes C, Bult P, Wobbes T.
    J Surg Oncol; 2007 Dec 01; 96(7):569-74. PubMed ID: 17680635
    [Abstract] [Full Text] [Related]

  • 14. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 15. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L, Xiang B, Muthuswamy SK.
    Cancer Res; 2006 May 15; 66(10):5201-8. PubMed ID: 16707444
    [Abstract] [Full Text] [Related]

  • 16. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
    Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.
    J Clin Oncol; 2005 Apr 10; 23(11):2502-12. PubMed ID: 15684311
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV, Ludeña MD, Varela G, García Pichel J.
    Lung Cancer; 2009 Jul 10; 65(1):25-33. PubMed ID: 19046792
    [Abstract] [Full Text] [Related]

  • 19. 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
    Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, Bernhaus A, Gueorguieva M, Richter S, Mader RM, Wesierska-Gadek J, Schott H, Szekeres T, Fritzer-Szekeres M, Krupitza G.
    Differentiation; 2006 Dec 10; 74(9-10):488-98. PubMed ID: 17177846
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.